All Blogs

Apr 18, 2018

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...

Apr 16, 2018

Signal Transducer and Activator of Transcription (STAT ) is a family of cytoplasmic transcription factors comprising of 7 members-STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The STAT factors are activated by tyrosine kinase which could be either receptor associated as Janus Kinase (JAKs) or intrinsic tyro...

Apr 13, 2018

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. The disease is a chronic form of acute inflammatory demyelinating poly...

Apr 12, 2018

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...

Apr 10, 2018

Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...

Mar 28, 2018

Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire's board and the proposal is at a "preparatory and exploratory" stage. No information about the investment was revealed by the Japanese drug ma...

Mar 28, 2018

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...

Mar 22, 2018

Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of ...

Mar 21, 2018

Precise pathological diagnosis is crucial for proper management of patients suffering from cancer. There are approximately 100 known tumor types of the central nervous system. Due to Large number of tumor type standardization of the diagnostic process is very challenging. Researchers are now working on a completely ...

Mar 20, 2018

Arbor Biotechnologies shining with new CRISPR enzyme Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has recently announced its first scientific discovery of a new enzyme, Cas13d, a CRISPR-Cas13 enzyme. It could offer advantag...